Finding Joy Again: Windmill Wellness Ranch Featured on Empowered with Meg Ryan
FORT LAUDERDALE, Fla., March 4, 2025 /PRNewswire/ -- Empowered with Meg Ryan explores how Windmill Wellness Ranch's holistic approach to mental health and substance abuse treatment is helping individuals and families rediscover joy and lasting well-being.
Empowered with Meg Ryan takes viewers on a journey to Windmill Wellness Ranch, a sanctuary dedicated to healing the root causes of mental health and substance abuse issues. This segment explores how Windmill's compassionate, individualized, and cutting-edge approach, including trauma-based therapies and strong family engagement, fosters long-lasting recovery and a return to joy. The program highlights the ranch's commitment to accurate diagnoses, significant therapist interaction, data-driven progress measurement, and robust aftercare support, including their unique Windmill Guarantee. This segment illustrates how Windmill empowers individuals to not just manage symptoms, but to achieve true wellness and reclaim their lives.
"Our approach at Windmill Wellness Ranch goes beyond traditional treatment. By blending advanced therapeutic techniques, scientific outcome data, and Brain Frequency™ technology, we address the root causes of mental health and substance abuse disorders. Rather than just managing symptoms, we work to uncover and treat the underlying issues through collaboration with master-level clinicians and psychiatrists, creating personalized treatment programs that lead to true, sustainable healing. Participating in Empowered with Meg Ryan allows us to showcase our commitment to empowering clients to reclaim their lives by treating the real issue, not just the diagnosis," stated Ani Narasimhan, CEO, Windmill Wellness Ranch.
Many individuals grappling with mental health and substance abuse face challenges that go beyond surface-level symptoms. Windmill Wellness Ranch's approach addresses the underlying issues, fostering deep healing and sustainable recovery. Their focus on family involvement, combined with individualized treatment plans, creates a supportive environment for lasting change.
About Empowered with Meg Ryan: Empowered with Meg Ryan is an award-winning program broadcast on Public Television stations nationwide. The program explores a variety of topics, offering viewers insightful perspectives on the world around them. Visit https://www.empoweredprogram.com/ to learn more.
About Windmill Wellness Ranch:
Windmill Wellness Ranch provides best-in-class substance abuse and mental health treatment services that lead to long-lasting healing and recovery. Visit https://windmillwellnessranch.com to learn more.
View original content to download multimedia:https://www.prnewswire.com/news-releases/finding-joy-again-windmill-wellness-ranch-featured-on-empowered-with-meg-ryan-302387608.html
SOURCE Empowered
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Spectral's seven director nominees were elected: Nominee Votes For (percent) Votes Withheld (percent) Jan D'Alvise 99.78% 0.22% Jun Hayakawa 99.79% 0.21% Chris Seto 89.39% 10.61% William Stevens 99.50% 0.50% Paul Walker 97.67% 2.33% David W. Feigal, Jr. 99.67% 0.33% Cristiano Franzi 99.78% 0.22% Appointment of Auditors MNP LLP, Chartered Accountants, was re-appointed as auditor of Spectral. Votes For: 99.95% Votes Withheld: 0.05% About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis The trial methods are detailed in 'Bayesian methods: a potential path forward for sepsis trials'. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company's ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter's commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact: Ali MahdaviCapital Markets & Investor RelationsSpinnaker Capital Markets Inc.416-962-3300am@
Yahoo
an hour ago
- Yahoo
Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The global Healthcare Simulation Market, valued at US$3.00 billion in 2024 stood at US$3.50 billion in 2025 and is projected to advance at a resilient CAGR of 15.6% from 2025 to 2030, culminating in a forecasted valuation of US$7.23 billion by the end of the period. This growth is likely to be driven by rising demand for standardized clinical training, increasing prevalence of chronic diseases, higher investment in healthcare technology, and more medical and nursing schools adopting simulation. Key contributors include patient simulators, interventional and cardiac surgical simulators, and simulation training services. Adoption is growing in hospitals and academic institutions, especially in North America and Asia Pacific. Governments are also supporting simulation-based training. For example, the University of Iowa received a USD 8-million grant from the Helmsley Charitable Trust to launch SIM-IA, a mobile simulation program for rural healthcare providers and first responders. Download PDF Brochure: Browse in-depth TOC on "Healthcare Simulation Market" 150 - Tables50 - Figures359 - Pages By Based on product & service, the healthcare simulation market, by product & service, is segmented into healthcare simulation anatomical models, healthcare simulation software, web-based simulation, and simulation training services. In 2024, the anatomical models accounted for the largest market share, driven by the increasing emphasis on patient safety and hands-on clinical training. These models allow medical students and professionals to practice procedures in a realistic, risk-free environment, enhancing clinical skills and reducing medical errors. As healthcare systems aim to improve efficiency and reduce costs, anatomical models are widely adopted as cost-effective alternatives to traditional training with live patients. Furthermore, the rising demand for minimally invasive procedures, ongoing advancements in surgical techniques, and growing funding for simulation-based education continue to boost their adoption in academic institutions and healthcare facilities, solidifying their position as the leading segment in the market. By Based on technology, the healthcare simulation market is segmented by technology into virtual patient simulation, 3D printing, and procedural rehearsal technology. Among these, the virtual patient simulation segment is expected to register the fastest growth rate during the forecast period due to its ability to provide immersive, risk-free, and repeatable training experiences for healthcare professionals. Leveraging virtual reality (VR) and augmented reality (AR) enables learners to practice clinical scenarios, decision-making, and patient interactions in highly realistic environments. This technology is particularly valuable for training in complex or rare medical cases that are difficult to encounter in real life. Several recent developments underscore this trend. For instance, in November 2024, VRAD Co., Ltd. launched NS_Core and IP_Trauma—two VR-based simulators for nursing and trauma care. Moreover, in July 2024, MediSim VR and KD Hospital opened India's first VR nurse training lab to enhance clinical skills through immersive simulation. These developments highlight the growing strategic focus on virtual patient simulation as a transformative tool in modern medical education and clinical training. By geography, in 2024, North America led the healthcare simulation market, mainly driven by sustained investments in mobile simulation technology and rural healthcare training. Notable initiatives include Washington State University's Mobile Simulation Program, launched in June 2024; the Simulation in Motion–Iowa (SIM-IA) program, launched in June 2022; and the Parkview Health Mobile Medical Training Lab (Indiana, USA), launched in May 2024. These programs are specifically designed to address the needs of underserved and rural communities, delivering high-fidelity simulation training directly to local healthcare providers. Such initiatives exemplify North America's commitment to expanding equitable access to simulation-based education. Furthermore, strong collaborations between academic institutions and healthcare systems, robust government support through initiatives such as the Health Resources and Services Administration (HRSA) grants, federal and state funding for mobile simulation units, and significant philanthropic funding have positioned North America as a global leader in healthcare simulation. These combined efforts enhance clinical preparedness, improve healthcare delivery, and ultimately strengthen patient outcomes across the region. Request Sample Pages : The key players functioning in the healthcare simulation market include CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), Simulaids (US), Intelligent Ultrasound Group PLC (UK), and Operative Experience Inc. (UK), and Surgical Science Sweden AB (Sweden), among others. CAE Inc. (Canada): CAE Inc. is a leader in simulation and training technologies, with a specialized Healthcare division offering high-fidelity patient simulators, ultrasound simulators, pediatric simulators, and surgical simulation systems. The company operates globally across 80+ countries, leveraging direct and partner-driven channels. CAE's core competencies include AR/VR integration, haptic feedback, and simulation center management. Major activities include strategic partnerships, acquisitions (e.g., Medicor), and R&D investments. CAE focuses on developing innovative training solutions, such as Vimedix and LucinaAR, and supports simulation research through collaborations with global universities, enhancing clinical skills and patient outcomes. Laerdal Medical (Norway) Laerdal Medical specializes in simulation-based training to improve patient outcomes, offering high-fidelity patient simulators, CPR manikins, and task trainers. The company's core competencies lie in scalable digital learning, resuscitation, and trauma care training. Major activities include acquisitions (e.g., B-Line Medical) and partnerships (e.g., SimX for VR simulation). Laerdal strongly focuses on innovation and adaptive learning, collaborating with global organizations such as the American Heart Association and GAVI. These initiatives enable Laerdal to lead in digital healthcare education and significantly advance clinical competency and patient safety. For more information, Inquire Now! Related Reports: Healthcare Education Market Healthcare Analytical Testing Services Market Healthcare IT Market Healthcare Analytics Market Remote Patient Monitoring Market Get access to the latest updates on Healthcare Simulation Companies and Healthcare Simulation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
Key presentations include two updates from a phase 3 trial evaluating investigational treatment with Mim8 (denecimig) and five assessing treatment outcomes with concizumab in hemophilia A phase 3 trial analysis from FRONTIER5 will evaluate the safety of switching directly from emicizumab to Mim8 (denecimig) in people living with hemophilia A/B Findings from explorer7 and explorer8 phase 3 trials will assess data including non-joint bleeds, annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B PLAINSBORO, N.J., June 6, 2025 /PRNewswire/ -- Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations across both hemophilia A and B (HA and HB), with and without inhibitors, will share insights on clotting, thrombin generation, bleeding episodes and medication impact, patient administration preferences, physician treatment satisfaction, and global real-world diagnosis and treatment data for joint bleeds. "At Novo Nordisk, we believe understanding the whole person and their journey is essential to addressing the unmet needs in people with hemophilia. Our research is rooted in a deep understanding of the hemophilia community, aiming to drive critical advancements across rare blood disorders in order to help address these unmet needs," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "Through this latest research, we are honored to build on our long-standing legacy in rare blood disorders to support patients who face the challenges of this complex condition." New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors.1 Analysis from the phase 3 FRONTIER5 trial will assess the safety and preferences of people with HA, with and without inhibitors, who switch from emicizumab to Mim8. In addition, new data from two prospective, multicenter, open label, phase 3 trials (explorer7 and explorer8) will investigate joint bleeds, non-joint bleeds, and annualized bleeding rate with preventive concizumab being investigated versus on-demand treatment across both HA and HB, with and without inhibitors. Summary of presentationsAccepted data at the 33rd ISTH Congress includes the following poster and oral presentations. Additional information can be found on the ISTH website. Full details of Novo Nordisk abstracts to be presented: Abstract title Abstract presentationdetails Hemophilia Investigational Mim8 FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab Oral presentation June 22 2:45-4:00 pm EST OC 20.4 Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5 Poster presentation June 23 1:45-2:45 pm EST PB0812 Mim8 enhances procoagulant activity of select hemophilia B-causing Factor IX variants (research collaboration) Oral presentation June 21 1:00-1:15 pm EST OC 03.1 Concizumab Non-joint bleeds in patients with hemophilia A or B with inhibitors: Concizumab explorer7 study Poster presentation June 23 1:45-2:45 pm EST PB0851 Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study Oral presentation June 24 2:45-4:00 pm EST OC 59.2 The effect of concizumab on thrombin generation in FVII deficient plasma Poster presentation June 24 1:45-2:45 pm EST PB1478 ISS study: TFPI slows prothombinase assembly when concizumab is bound to its second Kunitz domain Poster presentation June 24 1:45-2:45 pm EST PB1358 Taiwan study: Real-world efficacy of concizumab prophylaxis in a patient with hemophilia B and inhibitors Poster presentation June 23 1:45-2:45 pm EST PB0869 Pre-clinical data & general hemophilia In vitro activity of Inno8 in global hemostatic assays alone and with other hemostatic agents Oral presentation June 23 2:45-4:00 pm EST OC 39.5 Genomic integration of FVIII transgene in hepatocytes restores durable FVIII activity in vivo Oral presentation June 24 9:30-10:45 am EST OC 51.2 US physician-reported prophylactic treatment satisfaction and joint health of people with hemophilia Poster presentation June 24 1:45-2:45 pm EST PB1485 Joint bleed diagnosis and treatment delays in people with hemophilia: Global real-world data Poster presentation June 24 1:45-2:45 pm EST PB1423 About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.2 It is estimated to affect approximately 1,125,000 people worldwide.3 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).2 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy. However, sometimes the body can produce inhibitors as an immune response to the clotting factor replacement therapy. When this happens, the therapy may not work and can limit treatment options.5 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. MedlinePlus. Hemophilia. Accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al.; Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. Centers for Disease Control and Prevention (CDC). Treatment of hemophilia. Accessed May 2025. Available at Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25NNG00026 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Sign in to access your portfolio
